Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M3rTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWxc29KSzVyPUCuNFYyKM7:TR?= M1:wXnNCVkeHUh?=
ALL-PO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwME[zOVUh|ryP MYTTRW5ITVJ?
697 M{\Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPkTWM2OD1yLkC5PVc3KM7:TR?= M3PPbnNCVkeHUh?=
NCI-H748 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID4Z|NKSzVyPUCuNVA{OzRizszN M3vl[HNCVkeHUh?=
NKM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUC5NVIh|ryP NHnrWXJUSU6JRWK=
ES1 MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPETWM2OD1yLkGxNlU2KM7:TR?= M3nqZ3NCVkeHUh?=
NCI-H1963 NYDiT2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHhTWM2OD1yLkGxOVc6KM7:TR?= MUHTRW5ITVJ?
NCI-H1417 NGjlenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\LbXhQUUN3ME2wMlEzQTd2IN88US=> M{PqWXNCVkeHUh?=
NEC8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkc|JKSzVyPUCuNVM2OjdizszN NU\YXoc1W0GQR1XS
CRO-AP2 NYHKNI1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\MZ41iUUN3ME2wMlE3QDh7IN88US=> NG\4VIhUSU6JRWK=
A3-KAW M1Lodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnOPVNZUUN3ME2wMlE4PjJ5IN88US=> NWnHZot7W0GQR1XS
SF539 NFzWZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfzTWM2OD1yLkG5OVk{KM7:TR?= NUDWbnZsW0GQR1XS
NOS-1 M{\qdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G2cGlEPTB;MD6xPVYyQSEQvF2= M4C5PHNCVkeHUh?=
NTERA-S-cl-D1 NELhRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMkCxNVMh|ryP MVXTRW5ITVJ?
COR-L88 NIH1fodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TsXGlEPTB;MD6yNlk2QSEQvF2= MUfTRW5ITVJ?
EM-2 M{DkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnQXmNKSzVyPUCuNlQxPzlizszN MoH5V2FPT0WU
KARPAS-45 NX24SI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXxb4VKSzVyPUCuNlc5OzNizszN NGf1TI1USU6JRWK=
DSH1 M4TUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfxTHRNUUN3ME2wMlI5PzB6IN88US=> MkHJV2FPT0WU
HT-144 NETSRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\vdWlEPTB;MD6zNFI2PiEQvF2= NGrBR3JUSU6JRWK=
ATN-1 NWnhdZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwM{C1O|Yh|ryP NF;Y[ItUSU6JRWK=
HEL Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C3UmlEPTB;MD6zNVM1QCEQvF2= NWfpSlVvW0GQR1XS
NB12 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzITWM2OD1yLkOxO|U3KM7:TR?= M2jj[HNCVkeHUh?=
LU-139 NFXBUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLETWM2OD1yLkOzOVEh|ryP MWLTRW5ITVJ?
J-RT3-T3-5 NFmwRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GwRmlEPTB;MD6zN|cyPiEQvF2= MkHQV2FPT0WU
MOLT-13 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fUV2lEPTB;MD6zN|gyKM7:TR?= NWPpXohvW0GQR1XS
SR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXnSVlKSzVyPUCuN|QzPjFizszN NFfwVXFUSU6JRWK=
CMK M1rtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwM{W3Nlch|ryP MYrTRW5ITVJ?
ES8 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwM{[wNlIh|ryP NX;zT3F4W0GQR1XS
LB647-SCLC NIDYdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PNNWlEPTB;MD6zOlc{KM7:TR?= NWDKRWVUW0GQR1XS
TE-8 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfK[o1pUUN3ME2wMlM3QTN3IN88US=> MkLEV2FPT0WU
BV-173 NFO0ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHFc2FFUUN3ME2wMlM4OTJzIN88US=> NWLnO5dwW0GQR1XS
DEL Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnkTWM2OD1yLkO3OFg4KM7:TR?= M2nnSHNCVkeHUh?=
ARH-77 NHjmbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu5TWM2OD1yLkO4NVk{KM7:TR?= M1fCZ3NCVkeHUh?=
NCCIT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfBTWM2OD1yLkO4OlQ6KM7:TR?= MoDQV2FPT0WU
RPMI-8402 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPsdWFKSzVyPUCuN|g4ODFizszN NF76dlBUSU6JRWK=
MONO-MAC-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHpfnBKSzVyPUCuN|g4PzZizszN MXTTRW5ITVJ?
SK-MM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPOTWM2OD1yLkO5PFY5KM7:TR?= MWXTRW5ITVJ?
CHP-126 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1iyNmlEPTB;MD60NFI{OSEQvF2= MnH1V2FPT0WU
A101D NYjLUHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNECzJO69VQ>? MnW5V2FPT0WU
SCH NELNR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfpc|RKSzVyPUCuOFA{PDJizszN MUnTRW5ITVJ?
NMC-G1 NFjUTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTUWo5rUUN3ME2wMlQxOzZ5IN88US=> Moi5V2FPT0WU
NCI-H209 NVLXXVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jhOWlEPTB;MD60NFYyOyEQvF2= Mn63V2FPT0WU
MOLT-16 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNEGwNVch|ryP MXjTRW5ITVJ?
RPMI-6666 NVrjb4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNEGxNkDPxE1? NHS1XnpUSU6JRWK=
OPM-2 M3:4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnyWHRKSzVyPUCuOFE2OTNizszN M3HKUXNCVkeHUh?=
MRK-nu-1 NV7nRphlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfjTWM2OD1yLkSzNVU{KM7:TR?= MXjTRW5ITVJ?
BC-1 M2TxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrpNpFKSzVyPUCuOFM1ODNizszN MmrTV2FPT0WU
MHH-NB-11 NEixVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNEO0OVMh|ryP MVnTRW5ITVJ?
Ramos-2G6-4C10 NWLkWWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwNEO4PVch|ryP MkL5V2FPT0WU
LS-513 NX[1S3FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWNGlEPTB;MD60OFUxOSEQvF2= NG\ze4xUSU6JRWK=
K5 NUfkNm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDLZo5DUUN3ME2wMlQ4ODJ3IN88US=> MUTTRW5ITVJ?
HOP-62 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwNEizOVgh|ryP MnL6V2FPT0WU
NCI-H187 NYHKSJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;xe2lKSzVyPUCuOFkzOjdizszN MnrNV2FPT0WU
BE-13 NXvnNVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL1TWM2OD1yLkS5OlYyKM7:TR?= M4PXOHNCVkeHUh?=
HC-1 NXHtfVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwNUC0O|Mh|ryP NWKxb4JlW0GQR1XS
ACN NUHv[HI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTxRXdOUUN3ME2wMlUyODJ6IN88US=> M4L5NXNCVkeHUh?=
HCC1599 NF\odmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkntTWM2OD1yLkWxOVch|ryP NHniSmhUSU6JRWK=
MV-4-11 NVH2XlVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwNUOwOFEh|ryP MYDTRW5ITVJ?
LC-2-ad NV3nN5NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXifHZyUUN3ME2wMlU{PjZ|IN88US=> MVfTRW5ITVJ?
HL-60 NGjiNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwNUSyOlEh|ryP Mn7zV2FPT0WU
NB17 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvvUlJKSzVyPUCuOVQ{QCEQvF2= NEXxOIRUSU6JRWK=
TE-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17PR2lEPTB;MD61OVMxPiEQvF2= MXPTRW5ITVJ?
NCI-H524 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjlUW5KSzVyPUCuOVU1ODFizszN MYXTRW5ITVJ?
MZ7-mel Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwNU[xNFUh|ryP MnG0V2FPT0WU
L-363 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHEWpdWUUN3ME2wMlU3PjV5IN88US=> NF2xOnlUSU6JRWK=
BL-41 NHPiXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNU[4PFkh|ryP NWLBNJIzW0GQR1XS
LU-134-A NXPOSWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHXVHZKSzVyPUCuOVcxPzNizszN NVHxXXVjW0GQR1XS
SIG-M5 M2fRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwNUe4OFgh|ryP NH\jZ4NUSU6JRWK=
ONS-76 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvmTWM2OD1yLkW4NlQzKM7:TR?= NFLrR5hUSU6JRWK=
KARPAS-299 NFTNboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNUi1NFQh|ryP MlnsV2FPT0WU
DU-4475 NHjYNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK0[VVKSzVyPUCuOVg4ODNizszN M3;5SnNCVkeHUh?=
NB69 NXfXW|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDhVZN2UUN3ME2wMlU6QDJ3IN88US=> NIHIZ2hUSU6JRWK=
MHH-PREB-1 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNkC3NVkh|ryP NGqzfllUSU6JRWK=
LU-165 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmzTWM2OD1yLk[xPFEzKM7:TR?= M1\QR3NCVkeHUh?=
LOUCY NYm0UZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:zVmlEPTB;MD62N|M3PCEQvF2= MmTHV2FPT0WU
NCI-H526 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLDTWM2OD1yLk[zOVQyKM7:TR?= MlTZV2FPT0WU
KE-37 M1zrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jhVmlEPTB;MD62OFI4PiEQvF2= M4LSfnNCVkeHUh?=
NALM-6 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPVcppKSzVyPUCuOlQ5PiEQvF2= MVjTRW5ITVJ?
CW-2 M17CfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i2NWlEPTB;MD62OVc6PCEQvF2= M4SyZnNCVkeHUh?=
SU-DHL-1 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjMW3VKSzVyPUCuOlU6PDdizszN NXTsfYY2W0GQR1XS
NB13 NFzmXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHvTWM2OD1yLk[2PFE4KM7:TR?= MWXTRW5ITVJ?
QIMR-WIL NV:2[W5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m0WGlEPTB;MD62PFM1OyEQvF2= M4S3XHNCVkeHUh?=
ECC12 NFrGcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KzU2lEPTB;MD63NFA5PiEQvF2= MYfTRW5ITVJ?
KALS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwN{C0PVIh|ryP MlqwV2FPT0WU
COR-L279 NEnqWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHabZVKSzVyPUCuO|A6QTZizszN MV7TRW5ITVJ?
NB14 M4W1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnVSJJGUUN3ME2wMlczPjF5IN88US=> M2PYdnNCVkeHUh?=
CCRF-CEM NFu3dldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLaTWM2OD1yLke0OlYyKM7:TR?= MYjTRW5ITVJ?
SW954 M{DvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL2TWM2OD1yLke1PVk6KM7:TR?= MV;TRW5ITVJ?
IST-SL1 NGraOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu5O5k5UUN3ME2wMlc4OzR6IN88US=> NH;ZXG5USU6JRWK=
LAMA-84 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPoTWM2OD1yLke3OVY4KM7:TR?= Mlj6V2FPT0WU
Daudi Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;OR5NUUUN3ME2wMlc4PjhzIN88US=> NXfkTYdzW0GQR1XS
BC-3 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T2[WlEPTB;MD63PFMxQCEQvF2= NIrDN5FUSU6JRWK=
HCC2998 M{jQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwN{izOkDPxE1? MmjtV2FPT0WU
NCI-H69 M4TkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r0dGlEPTB;MD64NFE1PyEQvF2= NEHYZ5BUSU6JRWK=
CPC-N NXS0T|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwOEC1NlQh|ryP M1j0dHNCVkeHUh?=
NOMO-1 NFTWXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHTNWlKSzVyPUCuPFExQDRizszN MofUV2FPT0WU
CESS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwOEGxPVch|ryP NI\TO5ZUSU6JRWK=
LC4-1 M{HOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwOESwNFch|ryP MnPqV2FPT0WU
BL-70 NFewVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLXTG5KSzVyPUCuPFU4ODJizszN NH6xc3dUSU6JRWK=
ES4 NE\GSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\wZlNKSzVyPUCuPFU5PjhizszN M4jobHNCVkeHUh?=
HCE-T M4DiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwOEexO|Eh|ryP M4PpOHNCVkeHUh?=
JAR M4XIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwOEe4Nlch|ryP NY\4UHlmW0GQR1XS
ST486 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPobY1KSzVyPUCuPFc6OTdizszN M4Hnb3NCVkeHUh?=
KS-1 NYj6OpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nxPGlEPTB;MD64PFA6PiEQvF2= MWTTRW5ITVJ?
GDM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfTTWM2OD1yLki4Olg4KM7:TR?= NIHnbGpUSU6JRWK=
EHEB M1jlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjOTWM2OD1yLkmyOVg2KM7:TR?= MV\TRW5ITVJ?
LB2518-MEL NWP1[|JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z4VGlEPTB;MD65N|I5PCEQvF2= MXXTRW5ITVJ?
GOTO NIK3e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMTWM2OD1yLkm1NFc3KM7:TR?= NUCxbVJ7W0GQR1XS
LXF-289 M{fibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwOUW5NFEh|ryP MWfTRW5ITVJ?
ES6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwOU[0N|ch|ryP M3TrVHNCVkeHUh?=
OS-RC-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGwRVNoUUN3ME2wMlk3QDNizszN MWfTRW5ITVJ?
DMS-153 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPRSFJKSzVyPUCuPVc1PjlizszN MWrTRW5ITVJ?
SK-PN-DW M1rkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7jTWM2OD1yLkm3PFMyKM7:TR?= MUDTRW5ITVJ?
HH MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwOUi5OVkh|ryP MmrvV2FPT0WU
SH-4 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQdpZOUUN3ME2xMlAzPDFizszN MVzTRW5ITVJ?
MOLT-4 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3aTWM2OD1zLkCzOFU1KM7:TR?= NXq4TWVvW0GQR1XS
TGW MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfrcHh3UUN3ME2xMlA4Pjd3IN88US=> NEO4OFVUSU6JRWK=
L-540 NGe0W2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwMUC2NFQh|ryP MYPTRW5ITVJ?
PF-382 NGTBU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fBcGlEPTB;MT6xNVUyOyEQvF2= MU\TRW5ITVJ?
LC-1F NESwZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LiVWlEPTB;MT6xNlAxPyEQvF2= NYG1NINWW0GQR1XS
OVCAR-4 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwMUOxOlUh|ryP M{HhPHNCVkeHUh?=
A4-Fuk M3;Zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrKTWM2OD1zLkG1N|Y1KM7:TR?= NIrwSmNUSU6JRWK=
HCC2218 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7iZ4tKSzVyPUGuNVY3PDFizszN M{P3SXNCVkeHUh?=
HAL-01 NUHJZVQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[zTWM2OD1zLkG2PVQ{KM7:TR?= MlHsV2FPT0WU
IST-MEL1 NH3KUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny3TWM2OD1zLkG3OlU6KM7:TR?= MW\TRW5ITVJ?
NCI-H719 NUPacnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfJbGRlUUN3ME2xMlE4QDl6IN88US=> MkHPV2FPT0WU
EVSA-T MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\mTWM2OD1zLkG4NVE1KM7:TR?= NID5U2JUSU6JRWK=
SK-NEP-1 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jTT2lEPTB;MT6yNFI3PiEQvF2= NIrxbndUSU6JRWK=
OCUB-M MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS5TWM2OD1zLkKxOFg6KM7:TR?= NVvvTGNJW0GQR1XS
MEG-01 NXSwcWh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq1[HlZUUN3ME2xMlIzOTF6IN88US=> NUjxcplYW0GQR1XS
no-10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Id2lEPTB;MT6yN|EyOiEQvF2= M4HRfXNCVkeHUh?=
MHH-CALL-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\zR2lEPTB;MT6yOFczOSEQvF2= NV\VXGNCW0GQR1XS
SK-N-DZ NFLk[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHBeY9SUUN3ME2xMlI1Pzd4IN88US=> MWHTRW5ITVJ?
SCLC-21H MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TleGlEPTB;MT6yOlQ4QCEQvF2= MlrDV2FPT0WU
CTV-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H3S2lEPTB;MT6yO|QzPSEQvF2= NYTpW5BZW0GQR1XS
NB1 NVXsRZcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj3SFhKSzVyPUGuNlc4OzJizszN NFzDWpBUSU6JRWK=
NCI-H64 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXiNFRkUUN3ME2xMlI5PDZ{IN88US=> M3vQXnNCVkeHUh?=
MDA-MB-134-VI M1vVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT1cnZKSzVyPUGuNlg2PzdizszN NYnIbWN6W0GQR1XS
LB2241-RCC NHfvNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwMki2OlMh|ryP M{DxZXNCVkeHUh?=
8-MG-BA NIjiVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nSe2lEPTB;MT6yPFg3PiEQvF2= M4q1[nNCVkeHUh?=
LP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTjZpBiUUN3ME2xMlI6QTR5IN88US=> NWrFcGFxW0GQR1XS
LS-411N NVvvT3pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWxU3RWUUN3ME2xMlMxQTl6IN88US=> NYfHelc3W0GQR1XS
CAL-148 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX5TWM2OD1zLkOyOVQzKM7:TR?= NYix[VRPW0GQR1XS
NCI-H2171 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7rTWM2OD1zLkO0OVAzKM7:TR?= NX;tfYVIW0GQR1XS
JiyoyeP-2003 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCwZllVUUN3ME2xMlM2OzlizszN NFvx[YpUSU6JRWK=
NCI-H2107 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwM{W4PFMh|ryP MU\TRW5ITVJ?
BB30-HNC NVPFeFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHSWW5zUUN3ME2xMlM5QTd6IN88US=> MoXFV2FPT0WU
K-562 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz2TWM2OD1zLkO5NlE6KM7:TR?= M{XTd3NCVkeHUh?=
PSN1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37oXGlEPTB;MT60NlI5PyEQvF2= NVvGWW56W0GQR1XS
HCC2157 M1TDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwNEK2PVEh|ryP MUnTRW5ITVJ?
SBC-1 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwNEK3OFEh|ryP Ml;XV2FPT0WU
MC116 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\k[mliUUN3ME2xMlQ{PjF3IN88US=> NGPEb3VUSU6JRWK=
KARPAS-422 NHiyfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoeyTWM2OD1zLkS1N|U5KM7:TR?= Mmj6V2FPT0WU
LB996-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M331N2lEPTB;MT60O|ExOyEQvF2= NFrDfVhUSU6JRWK=
MSTO-211H NFzBb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vrRmlEPTB;MT60O|k5PyEQvF2= NVKwd2c6W0GQR1XS
BT-474 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDuVJpKSzVyPUGuOVE4PjRizszN MW\TRW5ITVJ?
A388 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnVPGpKSzVyPUGuOVE6PDVizszN MULTRW5ITVJ?
SJSA-1 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml74TWM2OD1zLkWyNlYh|ryP NEHwdZVUSU6JRWK=
COLO-829 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfObpRNUUN3ME2xMlU{PTZ2IN88US=> NGfWZVFUSU6JRWK=
KM-H2 NYHmeFRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG4VI5KSzVyPUGuOVY3PyEQvF2= NEHzdJRUSU6JRWK=
GR-ST M3XFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf0fIpKSzVyPUGuOVY5OiEQvF2= MYLTRW5ITVJ?
RPMI-8866 NXvzVmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nM[mlEPTB;MT62NFE1PCEQvF2= MlPtV2FPT0WU
KG-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zXWGlEPTB;MT62NVkxOSEQvF2= NXrU[YpLW0GQR1XS
NCI-H82 M3njTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LFbmlEPTB;MT62N|QxPiEQvF2= NWHpbXh4W0GQR1XS
LB1047-RCC NEjab|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwNkO0OVkh|ryP MU\TRW5ITVJ?
KM12 NH\GSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC5NWM5UUN3ME2xMlY1PyEQvF2= NHmwRo1USU6JRWK=
NB5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nWdWlEPTB;MT62OVY4PyEQvF2= NHTofo5USU6JRWK=
HDLM-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwNkiyPFEh|ryP M{jjWnNCVkeHUh?=
KU812 NGXCWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT4XIVpUUN3ME2xMlY6PjB3IN88US=> NVLSPHgxW0GQR1XS
DB MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfMR3Y3UUN3ME2xMlcxOzV|IN88US=> MnfpV2FPT0WU
HD-MY-Z NF31cHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LRN2lEPTB;MT63OVI{PCEQvF2= NXzhVpdtW0GQR1XS
KURAMOCHI M2DLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzDTWM2OD1zLke3NlA4KM7:TR?= NWfyTnlKW0GQR1XS
ETK-1 NXjQV4xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnNFNtUUN3ME2xMlc5QDd7IN88US=> NEjPV3hUSU6JRWK=
SK-UT-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H5fmlEPTB;MT63PVM5QCEQvF2= MVfTRW5ITVJ?
HUTU-80 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwN{m1NFgh|ryP NVPlclJQW0GQR1XS
ES7 M{LiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfTTWM2OD1zLkiwN|AzKM7:TR?= M4\mWnNCVkeHUh?=
SW872 NGLSU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNfHNKSzVyPUGuPFE{QTVizszN NFvpVmJUSU6JRWK=
TK10 NXjwTm4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3juUWlEPTB;MT64N|ExQCEQvF2= M1TQTXNCVkeHUh?=
LB831-BLC NYLKfHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX2Um9KSzVyPUGuPFM2PjNizszN MnfYV2FPT0WU
TE-9 NWDiNY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwOES0NlIh|ryP M1K5fXNCVkeHUh?=
MLMA MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLMSWZrUUN3ME2xMlg5OjN2IN88US=> MknuV2FPT0WU
D-542MG M2\oN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG4bWZKSzVyPUGuPFk{PzNizszN Mnz0V2FPT0WU
EW-16 NV\SSVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwOUK3NkDPxE1? NHTMNpBUSU6JRWK=
LOXIMVI MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74ZYlKSzVyPUGuPVMzQCEQvF2= M{DUV3NCVkeHUh?=
GB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfxTWM2OD1zLkmzPFY3KM7:TR?= Ml\0V2FPT0WU
IST-SL2 NYWwfFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwMECyOlIh|ryP MX\TRW5ITVJ?
LAN-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwMEG5OlYh|ryP MkH4V2FPT0WU
NCI-H510A MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX1fIpjUUN3ME2yMlA1PTB{IN88US=> M4nUXXNCVkeHUh?=
NCI-H1092 M{HnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7POpJKSzVyPUKuNFUyOjRizszN MU\TRW5ITVJ?
HT M4PNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfsWpBxUUN3ME2yMlExPDV2IN88US=> NWfmU3d7W0GQR1XS
RL95-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwMUG0PFIh|ryP NInU[HNUSU6JRWK=
NCI-H1355 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfJTWM2OD1{LkGxO|kzKM7:TR?= M1y5PHNCVkeHUh?=
NCI-H720 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnTOJRJUUN3ME2yMlE3QDd|IN88US=> NWfScYZoW0GQR1XS
NCI-H1522 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HvXWlEPTB;Mj6yNVczOyEQvF2= NGTOdnRUSU6JRWK=
LB373-MEL-D NFXzWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwMk[5NFIh|ryP MlHrV2FPT0WU
DG-75 M3nLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zVZWlEPTB;Mj6yO|E1QCEQvF2= MV3TRW5ITVJ?
ML-2 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwM{K4OVUh|ryP MoPSV2FPT0WU
SF126 NGHROlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PD[GlEPTB;Mj6zN|A6PCEQvF2= NGi4NppUSU6JRWK=
MPP-89 NYrGUlVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwM{OxOFUh|ryP MoG1V2FPT0WU
NCI-H345 NGPneVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwM{OyO|ch|ryP MVnTRW5ITVJ?
LS-123 NIPJXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS1d4U1UUN3ME2yMlM1QTN4IN88US=> MYHTRW5ITVJ?
NB10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3ST5dKSzVyPUKuOFExQTJizszN NUXRVY1tW0GQR1XS
CGTH-W-1 NImxSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTGTWM2OD1{LkSyNlY4KM7:TR?= M1jGe3NCVkeHUh?=
CP66-MEL M1\mRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwNEe3O{DPxE1? M13w[3NCVkeHUh?=
L-428 M3HqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnGSINKSzVyPUKuOFg2OjFizszN MVPTRW5ITVJ?
DMS-79 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nVOmlEPTB;Mj61OFExOyEQvF2= M2nnV3NCVkeHUh?=
NCI-H1882 NUXPb5hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwNke1OlIh|ryP MmPKV2FPT0WU
KGN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD1{Lke2PFc3KM7:TR?= MojSV2FPT0WU
EW-1 NVfTUpdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLlTVBKSzVyPUKuO|cxQDNizszN M3eze3NCVkeHUh?=
U-266 NVPye2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwOES4NlMh|ryP MV;TRW5ITVJ?
COLO-320-HSR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwOEW2OFEh|ryP NHHT[nBUSU6JRWK=
KMOE-2 NFXnU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwOEe3NVEh|ryP NInYOXVUSU6JRWK=
BB49-HNC M4jNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\QOWlEPTB;Mj65NlQ5KM7:TR?= MWPTRW5ITVJ?
GI-1 M3jMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrVWlEPTB;Mj65Nlk2PyEQvF2= M4XubHNCVkeHUh?=
NCI-H1304 NU[2dHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq4TWM2OD1|LkCwOVEyKM7:TR?= Mn\zV2FPT0WU
NCI-H2227 NILucJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwMEKwO|kh|ryP MVTTRW5ITVJ?
U-87-MG M2\ENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHRTWM2OD1|LkCzOVE{KM7:TR?= NYPiN2luW0GQR1XS
NCI-H747 M1HLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojITWM2OD1|LkC1NlA3KM7:TR?= MUXTRW5ITVJ?
CTB-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K5V2lEPTB;Mz6wOVM4PiEQvF2= NXjmXHRHW0GQR1XS
RPMI-8226 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP5TWM2OD1|LkG0N|c5KM7:TR?= NYC2WW1vW0GQR1XS
NCI-H2141 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjQZ3VKSzVyPUOuNVY2PjZizszN NGnORZhUSU6JRWK=
IST-MES1 M3PLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLxcoE2UUN3ME2zMlE5Ojd7IN88US=> M4DwfXNCVkeHUh?=
TE-5 M{W2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml73TWM2OD1|LkKxN|QzKM7:TR?= NUS2U2dlW0GQR1XS
UACC-257 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLSPWpKSzVyPUOuOFM3PTlizszN MWDTRW5ITVJ?
SK-N-FI Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWezV21jUUN3ME2zMlQ2OjJ5IN88US=> NWHTVYIyW0GQR1XS
MFH-ino NUnZd5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwNE[1PFkh|ryP MmHEV2FPT0WU
SF268 NXTuWXV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDRTWM2OD1|LkS4NVc1KM7:TR?= M4m3TXNCVkeHUh?=
TE-12 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknXTWM2OD1|LkWxOlk6KM7:TR?= NGXMVYhUSU6JRWK=
NB6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrCU3VvUUN3ME2zMlU2PTZ|IN88US=> M3LpfHNCVkeHUh?=
DJM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNwNUm4PVkh|ryP MkHzV2FPT0WU
MZ1-PC NUXqPY96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrxTWM2OD1|Lk[xOlI1KM7:TR?= M1fXWnNCVkeHUh?=
OCI-AML2 NHzuRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHNZpdxUUN3ME2zMlYzPjdzIN88US=> MYrTRW5ITVJ?
NCI-H1155 NXTK[W8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrUNGQyUUN3ME2zMlcxQTR5IN88US=> MnrXV2FPT0WU
RKO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC1PHVKSzVyPUOuO|cyQDlizszN M3TKTHNCVkeHUh?=
ECC4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiwTWM2OD1|Lkm3NVk2KM7:TR?= NFLnTWRUSU6JRWK=
BB65-RCC NIfVTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL2PJp6UUN3ME2zMlk4PTR5IN88US=> MV;TRW5ITVJ?
EB-3 M3jD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHxTWM2OD1|Lkm5OlM{KM7:TR?= M17RfHNCVkeHUh?=
SHP-77 NFnYfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrsTWM2OD12LkCwOVI1KM7:TR?= MWPTRW5ITVJ?
NCI-H2196 NH\ue3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W5W2lEPTB;ND6wOVYzPSEQvF2= NGTZfXhUSU6JRWK=
GI-ME-N MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjk[o1DUUN3ME20MlA3Ozl7IN88US=> NFLX[4hUSU6JRWK=
MN-60 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;qRVhKSzVyPUSuNVA5PyEQvF2= MULTRW5ITVJ?
NCI-H1694 M3XNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTSPFJKSzVyPUSuNVM1ODVizszN MVrTRW5ITVJ?
LU-65 NH74PFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvDTWM2OD12LkG1N|MzKM7:TR?= M3nSTHNCVkeHUh?=
NCI-H1436 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XKNGlEPTB;ND6xPFM{OyEQvF2= M4\1SXNCVkeHUh?=
KINGS-1 M2Lu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LTV2lEPTB;ND6zNVQ{OiEQvF2= M2DvcnNCVkeHUh?=
GT3TKB NVfQfG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjGSJA3UUN3ME20MlM{OjZ6IN88US=> M2HXXHNCVkeHUh?=
Becker MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwM{ezNVIh|ryP NFP2S5pUSU6JRWK=
HCC1187 M1fyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRwOEm2OVch|ryP M3LveHNCVkeHUh?=
D-502MG NYDuTmw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5TWM2OD13LkCwOFE3KM7:TR?= MmLxV2FPT0WU
VA-ES-BJ M4\mTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rSUmlEPTB;NT6xN|c4QCEQvF2= NYq4bJQ5W0GQR1XS
NB7 NXLNOFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnHR4lPUUN3ME21MlE1OTF{IN88US=> NY\I[o12W0GQR1XS
SW962 NETldFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfIcYtKSzVyPUWuN|g5OTRizszN NITaTXhUSU6JRWK=
no-11 M3rxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvKTWM2OD13Lke2N|Q{KM7:TR?= M3H1V3NCVkeHUh?=
KNS-81-FD MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPFTWM2OD13LkmwOlk1KM7:TR?= MYrTRW5ITVJ?
COLO-684 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WyVWlEPTB;NT65PVQ6PCEQvF2= NFnlfGJUSU6JRWK=
D-263MG NFTLN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLpbVBKSzVyPU[uNFg5QTVizszN NYjYXmZTW0GQR1XS
EW-24 NEfBU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZwMki1NUDPxE1? M{D1UnNCVkeHUh?=
TE-10 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fLWWlEPTB;Nj60NlYzOyEQvF2= MVPTRW5ITVJ?
EKVX MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVW|RWUUN3ME22MlQ3OzJzIN88US=> MVXTRW5ITVJ?
NCI-H1648 M2D4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PGeGlEPTB;Nj62O|U2PyEQvF2= NH\wc4pUSU6JRWK=
LB771-HNC NGfmVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn0TWM2OD14LkmyN|AyKM7:TR?= NWLGWId4W0GQR1XS
SK-MEL-1 NXX6OIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjzOow{UUN3ME24MlE{OTZ4IN88US=> MWXTRW5ITVJ?
COLO-668 NYD5dHlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn32TWM2OD16LkK3O|g3KM7:TR?= MVHTRW5ITVJ?
EW-12 MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\vb2lEPTB;OD60NFgxOyEQvF2= MVrTRW5ITVJ?
A253 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;WV3RKSzVyPUiuPFQ3PjFizszN NF3OSY5USU6JRWK=
NCI-H2126 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0VY9xUUN3ME24Mlg6OzF7IN88US=> NWXsRnZxW0GQR1XS
Calu-6 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13PVmlEPTB;OD65PVA1OiEQvF2= MXnTRW5ITVJ?
NCI-H23 M{Lt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjKTWM2OD17LkG3O|Q3KM7:TR?= MUHTRW5ITVJ?
WSU-NHL MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTlwN{e0O|gh|ryP MkPZV2FPT0WU
MMAC-SF M3nPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn2fFhIUUN3ME25Mlk4QTB2IN88US=> M2foeXNCVkeHUh?=
SK-LMS-1 NHHYS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFyLkK4N|Qh|ryP MUjTRW5ITVJ?
GCIY M{XlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFyLkW5NlQh|ryP NYPoRVFEW0GQR1XS
TE-15 NF\JdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzJOGZKSzVyPUGxMlYxODRizszN Ml7sV2FPT0WU
EoL-1-cell M4i4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;vbGlEPTB;MUGuO|Y5OiEQvF2= M1fQSXNCVkeHUh?=
NCI-H2081 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvvTWM2OD1zMT63O|g3KM7:TR?= MkDSV2FPT0WU
EW-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF{LkK0OlMh|ryP MXzTRW5ITVJ?
CAS-1 NUmydY13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vRcGlEPTB;MUKuN|Y{OSEQvF2= M3W0cHNCVkeHUh?=
C2BBe1 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm2TWM2OD1zMj62NVMyKM7:TR?= NHy0enBUSU6JRWK=
D-247MG NHmxSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXZNoduUUN3ME2xNk44QTV{IN88US=> NH\Bd4lUSU6JRWK=
NCI-SNU-5 NU\EWYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X5XGlEPTB;MUKuPFAyOyEQvF2= M17ic3NCVkeHUh?=
LS-1034 M4OwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZWmlEPTB;MUSuN|k4PSEQvF2= NXr2bm1PW0GQR1XS
EW-18 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnriTWM2OD1zND60OFgh|ryP MofqV2FPT0WU
Raji NHr6SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF2LkWwOFkh|ryP MX\TRW5ITVJ?
D-283MED NGraS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF2Lk[yO|Eh|ryP NInyT5VUSU6JRWK=
MZ2-MEL M4OxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF2Lkm2PVYh|ryP NVnScmozW0GQR1XS
NCI-SNU-16 NXrx[XpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH36Sm9KSzVyPUG1MlQ3OzNizszN MVjTRW5ITVJ?
P30-OHK NVrlcJhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF5Lke4N|Eh|ryP MV7TRW5ITVJ?
RXF393 NFnvUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPJTWM2OD1zOT6wNVg3KM7:TR?= M2HqZXNCVkeHUh?=
NCI-H1395 NX\wZm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJyLk[3NFMh|ryP NXLIVmhRW0GQR1XS
U-698-M M13EOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJyLkewO|Uh|ryP NIPv[3NUSU6JRWK=
NCI-SNU-1 NEXUT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTwTWM2OD1{MD63NlI{KM7:TR?= MX;TRW5ITVJ?
SW684 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjpTZBKSzVyPUKxMlE4OTZizszN NULRW25LW0GQR1XS
NCI-H716 M4\tUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSxTWM2OD1{MT6zNVU1KM7:TR?= MmHpV2FPT0WU
JVM-2 NV\pRmhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vpRmlEPTB;MkGuOFE{OyEQvF2= NYCyRoE1W0GQR1XS
NCI-H1581 NFjlWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ{LkSxOFgh|ryP NWW0fGtlW0GQR1XS
CA46 M33EXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\rTWM2OD1|MT62PVM3KM7:TR?= MXjTRW5ITVJ?
SNB75 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN|Lk[1NFMh|ryP MlfrV2FPT0WU
KNS-42 NULQZ5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X2UGlEPTB;M{WuPVYzPCEQvF2= M2j0VnNCVkeHUh?=
TUR M2[2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixcXpjUUN3ME2zOk4xPTJzIN88US=> NVriPIlVW0GQR1XS
REH MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN5LkiyNVEh|ryP NVfaTo5OW0GQR1XS
EW-22 NI\xfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M176UGlEPTB;NEKuNlg5PSEQvF2= Mn\BV2FPT0WU
NCI-H446 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPVWVRlUUN3ME20Nk44QDV|IN88US=> NWjFVZB7W0GQR1XS
ES3 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjxVGlPUUN3ME20N{4yOzN7IN88US=> Mn;zV2FPT0WU
EW-11 M4PGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TpN2lEPTB;NESuPFIyQCEQvF2= NHPi[YVUSU6JRWK=
RH-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfuOG1KSzVyPUS3MlU5OTJizszN MlW4V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals December 15 2018 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03538171 Recruiting Advanced Breast Cancer EddingPharm Oncology Co. LTD. May 15 2018 Phase 3
NCT03501381 Recruiting Renal Cell Carcinoma Roberto Pili|Indiana University Melvin and Bren Simon Cancer Center|Prometheus Laboratories|Syndax Pharmaceuticals|Hoosier Cancer Research Network May 24 2018 Phase 2
NCT02697630 Recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals February 21 2018 Phase 2
NCT03361800 Recruiting Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) January 22 2018 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID